SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Abamectin Liquid Formulation

Manufacturer or supplier’s details
Company name of supplier: MSD
Address: Avenida 16 de Septiembre No. 301
Xaltocan - Xochimilco Mexico 16090
Telephone: 52 55 57284444
Telefax: 908-735-1496
Emergency telephone: 1-908-423-6000
E-mail address: EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use: Veterinary product

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification
Acute toxicity (Oral): Category 5
Acute toxicity (Inhalation): Category 4
Reproductive toxicity: Category 2
Specific target organ toxicity - repeated exposure (Oral): Category 1 (Central nervous system)
Specific target organ toxicity - repeated exposure: Category 2 (Central nervous system)

GHS label elements
Hazard pictograms: 

Signal Word: Danger

Hazard Statements
H303 May be harmful if swallowed.
H332 Harmful if inhaled.
H361fd Suspected of damaging fertility. Suspected of damaging the unborn child.
H372 Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.
H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

Precautionary Statements
Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe mist or vapors.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P271 Use only outdoors or in a well-ventilated area.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P304 + P340 + P312 IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing. Call a POISON CENTER or doctor/ physician if you feel unwell.
P312 Call a POISON CENTER or doctor/ physician if you feel unwell.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abamectin (combination of avermectin B1a and avermectin B1b)</td>
<td>71751-41-2</td>
<td>&gt;= 1 -&lt; 5</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
SAFETY DATA SHEET
Abamectin Liquid Formulation

Most important symptoms and effects, both acute and delayed:
- May be harmful if swallowed.
- Harmful if inhaled.
- Suspected of damaging fertility. Suspected of damaging the unborn child.
- Causes damage to organs through prolonged or repeated exposure if swallowed.
- May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders:
- First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician:
- Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media:
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media:
- None known.

Specific hazards during fire fighting:
- Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Carbon oxides

Specific extinguishing methods:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

Special protective equipment for fire-fighters:
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
- Use personal protective equipment.
- Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions:
- Discharge into the environment must be avoided.
- Prevent further leakage or spillage if safe to do so.
- Prevent spreading over a wide area (e.g., by containment or oil barriers).
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
- Soak up with inert absorbent material.
- For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
- Clean up remaining materials from spill with suitable...
absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling: Do not breathe vapors or spray mist. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage: Keep in properly labeled containers. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents Organic peroxides Explosives Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abamectin (combination of avermectin B1a and avermectin B7)</td>
<td>71751-41-2</td>
<td>TWA</td>
<td>30 µg/m3 (OEB 3)</td>
<td>Internal</td>
</tr>
</tbody>
</table>
Abamectin Liquid Formulation

<table>
<thead>
<tr>
<th>tin B1b)</th>
<th>Wipe limit</th>
<th>300 µg/100 cm²</th>
<th>Internal</th>
</tr>
</thead>
</table>

**Engineering measures**: Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

**Personal protective equipment**

**Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type**: Combined particulates and organic vapor type

**Hand protection**

**Material**: Chemical-resistant gloves

**Remarks**: Consider double gloving.

**Eye protection**: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection**: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

**Appearance**: liquid

**Color**: light yellow

**Odor**: characteristic

**Odor Threshold**: No data available

**pH**: No data available

**Melting point/freezing point**: No data available

**Initial boiling point and boiling range**: No data available
SAFETY DATA SHEET

Abamectin Liquid Formulation

Flash point : No data available
Evaporation rate : No data available
Flammability (solid, gas) : Not applicable
Flammability (liquids) : No data available
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapor pressure : No data available
Relative vapor density : No data available
Relative density : No data available
Density : 0.90 - 0.94 g/cm³
Solubility(ies)
   Water solubility : insoluble
Partition coefficient: n-octanol/water : Not applicable
Autoignition temperature : No data available
Decomposition temperature : No data available
Viscosity
   Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : No data available
Particle size : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reac-
tions : Can react with strong oxidizing agents.
Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.
SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
May be harmful if swallowed.
Harmful if inhaled.

Product:
Acute oral toxicity: Acute toxicity estimate: 2,400 mg/kg
Method: Calculation method

Acute inhalation toxicity: Acute toxicity estimate: 2.3 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: Calculation method

Acute dermal toxicity: Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:
Abamectin (combination of avermectin B1a and avermectin B1b):
Acute oral toxicity: LD50 (Rat): 24 mg/kg
    LD50 (Mouse): 10 mg/kg
    LDLo (Monkey): 24 mg/kg
    Symptoms: Dilatation of the pupil

Acute inhalation toxicity: LC50 (Rat): 0.023 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Rat): 330 mg/kg
    LD50 (Rabbit): 2,000 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:
Abamectin (combination of avermectin B1a and avermectin B1b):
Species: Rabbit
Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.
Components:

**Abamectin (combination of avermectin B1a and avermectin B1b):**
Species : Rabbit
Result : Mild eye irritation

Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Components:

**Abamectin (combination of avermectin B1a and avermectin B1b):**
Test Type : Maximization Test
Routes of exposure : Skin contact
Result : Not a skin sensitizer.

Germ cell mutagenicity
Not classified based on available information.

Components:

**Abamectin (combination of avermectin B1a and avermectin B1b):**
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative
Test Type: Alkaline elution assay
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Carcinogenicity
Not classified based on available information.

Components:

**Abamectin (combination of avermectin B1a and avermectin B1b):**
Species : Rat
Application Route : Oral
Exposure time : 105 weeks
Result : negative
Species : Mouse
Application Route: Oral
Exposure time: 93 weeks
Result: negative

Reproductive toxicity
Suspected of damaging fertility. Suspected of damaging the unborn child.

Components:

Abamectin (combination of avermectin B1a and avermectin B1b):
Effects on fertility: Test Type: Fertility
Species: Rat, male
Application Route: Oral
Result: Effects on fertility.

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Early Embryonic Development: NOAEL: 0.12 mg/kg body weight
Result: Fetotoxicity.

Effects on fetal development: Test Type: Embryo-fetal development
Species: Mouse
Application Route: Oral
General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
Result: Cleft palate
Remarks: Adverse developmental effects were observed

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 2 mg/kg body weight
Result: Cleft palate, Teratogenic effects., Reduced embryonic survival
Remarks: Adverse developmental effects were observed

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 1.6 mg/kg body weight
Result: Teratogenic effects.

Reproductive toxicity - Assessment: Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

STOT-single exposure
Not classified based on available information.
STOT-repeated exposure
Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.
May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

Components:
Abamectin (combination of avermectin B1a and avermectin B1b):
Routes of exposure : Ingestion
Target Organs : Central nervous system
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:
Abamectin (combination of avermectin B1a and avermectin B1b):
Species : Rat
NOAEL : 1.5 mg/kg
Application Route : Oral
Exposure time : 24 Months
Target Organs : Central nervous system
Symptoms : Tremors, ataxia

Species : Mouse
NOAEL : 4.0 mg/kg
Application Route : Oral
Exposure time : 24 Months
Target Organs : Central nervous system
Symptoms : Tremors, ataxia

Species : Dog
NOAEL : 0.25 mg/kg
LOAEL : 0.5 mg/kg
Application Route : Oral
Exposure time : 53 Weeks
Target Organs : Central nervous system
Symptoms : Tremors, weight loss
Remarks : mortality observed

Species : Monkey
NOAEL : 1.0 mg/kg
Application Route : Oral
Exposure time : 14 Weeks
Target Organs : Central nervous system

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:
Abamectin (combination of avermectin B1a and avermectin B1b):
Ingestion:
Symptoms: May cause, Tremors, Diarrhea, central nervous system effects, Salivation, tearing

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Abamectin (combination of avermectin B1a and avermectin B1b):

Toxicity to fish:
- LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 µg/l Exposure time: 96 h
- LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l Exposure time: 96 h
- LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l Exposure time: 96 h
- LC50 (Cyprinus carpio (Carp)): 42 µg/l Exposure time: 96 h
- LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates:
- EC50 (Americamysis): 0.022 µg/l Exposure time: 96 h
- EC50 (Daphnia magna (Water flea)): 0.34 µg/l Exposure time: 48 h

Toxicity to algae/aquatic plants:
- EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l Exposure time: 72 h

Toxicity to fish (Chronic toxicity):
- NOEC (Pimephales promelas (fathead minnow)): 0.52 µg/l Exposure time: 32 d

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
- NOEC (Daphnia magna (Water flea)): 0.03 µg/l Exposure time: 21 d
  - NOEC (Mysisoposis bahia (opossum shrimp)): 0.0035 µg/l Exposure time: 28 d

Toxicity to microorganisms:
- EC50: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition

Persistence and degradability

Components:

Abamectin (combination of avermectin B1a and avermectin B1b):

Stability in water:
Hydrolysis: 50 %(< 12 h)
Bioaccumulative potential

Components:

**Abamectin (combination of avermectin B1a and avermectin B1b):**

Bioaccumulation  :  Bioconcentration factor (BCF): 52

Partition coefficient: n-octanol/water  :  log Pow: 4

Mobility in soil

Components:

**Abamectin (combination of avermectin B1a and avermectin B1b):**

Distribution among environmental compartments  :  log Koc: > 3.6

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

**UNRTDG**

| UN number | : | UN 3082 |
| Proper shipping name | : | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Abamectin (combination of avermectin B1a and avermectin B1b)) |

| Class | : | 9 |
| Packing group | : | III |
| Labels | : | 9 |

**IATA-DGR**

| UN/ID No. | : | UN 3082 |
| Proper shipping name | : | Environmentally hazardous substance, liquid, n.o.s. (Abamectin (combination of avermectin B1a and avermectin B1b)) |

| Class | : | 9 |
| Packing group | : | III |
| Labels | : | Miscellaneous |
| Packing instruction (cargo aircraft) | : | 964 |
| Packing instruction (passenger aircraft) | : | 964 |
| Environmentally hazardous | : | yes |
IMDG-Code
UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Abamectin (combination of avermectin B1a and avermectin B1b))

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation
NOM-002-SCT
UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Abamectin (combination of avermectin B1a and avermectin B1b))

Class : 9
Packing group : III
Labels : 9

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture
Federal Law for the control of chemical precursors, essential chemical products and machinery for producing capsules, tablets and pills. : Not applicable

The ingredients of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations
<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
</table>


Revision Date: 13.09.2019

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX / Z8